| abstract |
A histamine H3 receptor antagonist is provided, and metabolic diseases such as obesity and diabetes, for example, various diseases such as angina pectoris, acute and congestive heart failure, such as idiopathic hypersomnia, recurrent hypersomnia, etc. The present invention provides a therapeutic and / or prophylactic agent for central and peripheral nervous system diseases such as systemic diseases such as bulimia, affective disorders, and depression. General formula (I) [wherein X 1 and X 2 independently represent a nitrogen atom or CH, Y represents a specific group, X 3 represents O s — (CH 2 ) m , and R 1 and R 2 independently represents a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms, s represents 0 or 1, m represents an integer such that (m + s) is 0 or 1 to 4. Or a pharmaceutically acceptable salt thereof, wherein the histamine H3 receptor antagonist is characterized by comprising: |